{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T05:32:11Z","timestamp":1780464731538,"version":"3.54.1"},"reference-count":52,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100005010","name":"Associazione Italiana per la Ricerca sul Cancro","doi-asserted-by":"publisher","award":["12237"],"award-info":[{"award-number":["12237"]}],"id":[{"id":"10.13039\/501100005010","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thrombosisresearch.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Thrombosis Research"],"published-print":{"date-parts":[[2022,5]]},"DOI":"10.1016\/j.thromres.2022.01.019","type":"journal-article","created":{"date-parts":[[2022,5,26]],"date-time":"2022-05-26T08:28:09Z","timestamp":1653553689000},"page":"S46-S50","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"S1","title":["Hemostatic system activation in breast cancer: Searching for new biomarkers for cancer risk prediction and outcomes"],"prefix":"10.1016","volume":"213","author":[{"given":"Marina","family":"Marchetti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Russo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cinzia","family":"Giaccherini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Gamba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Falanga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.thromres.2022.01.019_bb0005","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1111\/jth.12075","article-title":"Coagulation, and cancer: biological and clinical aspects","volume":"11","author":"Falanga","year":"2013","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.thromres.2022.01.019_bb0010","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/978-3-030-20315-3_2","article-title":"Pathophysiology 1. Mechanisms of thrombosis in cancer patients","volume":"179","author":"Falanga","year":"2019","journal-title":"Cancer Treat. Res."},{"issue":"8","key":"10.1016\/j.thromres.2022.01.019_bb0015","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1055\/s-0041-1733925","article-title":"Hemostatic biomarkers and cancer prognosis: where do we stand?","volume":"47","author":"Falanga","year":"2021","journal-title":"Semin. Thromb. Hemost."},{"issue":"1","key":"10.1016\/j.thromres.2022.01.019_bb0020","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1186\/s13045-020-00932-z","article-title":"Beyond thrombosis: the impact of tissue factor signaling in cancer","volume":"13","author":"Unruh","year":"2020","journal-title":"J. Hematol. Oncol."},{"issue":"4","key":"10.1016\/j.thromres.2022.01.019_bb0025","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1055\/s-0039-1687891","article-title":"Oncogenes and clotting factors: the emerging role of tumor cell genome and epigenome in cancer-associated thrombosis","volume":"45","author":"Tawil","year":"2019","journal-title":"Semin. Thromb. Hemost."},{"issue":"15","key":"10.1016\/j.thromres.2022.01.019_bb0030","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1182\/blood.2020007488","article-title":"Genomic profiling identifies somatic mutations predicting thromboembolic risk in patients with solid tumors","volume":"137","author":"Dunbar","year":"2021","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.thromres.2022.01.019_bb0035","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1182\/blood-2004-05-2042","article-title":"Oncogenic events regulate tissue factor expression in colorectal cancer cells: implications for tumor progression and angiogenesis","volume":"105","author":"Yu","year":"2005","journal-title":"Blood"},{"issue":"Suppl 1","key":"10.1016\/j.thromres.2022.01.019_bb0040","doi-asserted-by":"crossref","first-page":"S37","DOI":"10.1016\/S0049-3848(20)30395-9","article-title":"Hemostatic biomarkers in occult cancer and cancer risk prediction","volume":"191","author":"Marchetti","year":"2020","journal-title":"Thromb. Res."},{"issue":"8","key":"10.1016\/j.thromres.2022.01.019_bb0045","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1055\/s-0041-1733925","article-title":"Hemostatic biomarkers and cancer prognosis: where do we stand?","volume":"47","author":"Falanga","year":"2021","journal-title":"Semin. Thromb. Hemost."},{"issue":"3","key":"10.1016\/j.thromres.2022.01.019_bb0050","first-page":"209","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J. Clin."},{"issue":"5","key":"10.1016\/j.thromres.2022.01.019_bb0055","first-page":"363","article-title":"Cancer treatment and survivorship statistics, 2019","volume":"69","author":"Miller","year":"2019"},{"issue":"10","key":"10.1016\/j.thromres.2022.01.019_bb0060","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12102767","article-title":"Non-invasive biomarkers for early detection of breast cancer","volume":"12","author":"Li","year":"2020","journal-title":"Cancers"},{"issue":"4","key":"10.1016\/j.thromres.2022.01.019_bb0065","doi-asserted-by":"crossref","first-page":"162","DOI":"10.5152\/ejbh.2017.3635","article-title":"Reliable biomarkers to identify new and recurrent cancer","volume":"13","author":"Sauter","year":"2017","journal-title":"Eur. J. Breast Health"},{"issue":"4","key":"10.1016\/j.thromres.2022.01.019_bb0070","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1002\/ijc.2910420414","article-title":"Human breast and colon carcinomas express cysteine proteinase activities with pro-aggregating and pro-coagulant properties","volume":"42","author":"Grignani","year":"1988","journal-title":"Int. J. Cancer"},{"issue":"4","key":"10.1016\/j.thromres.2022.01.019_bb0075","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1016\/j.thromres.2011.03.006","article-title":"All trans-retinoic acid modulates the procoagulant activity of human breast cancer cells","volume":"128","author":"Marchetti","year":"2011","journal-title":"Thromb. Res."},{"issue":"14","key":"10.1016\/j.thromres.2022.01.019_bb0080","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22147731","article-title":"Retinoids as chemo-preventive and molecular-targeted anti-cancer therapies","volume":"22","author":"Hunsu","year":"2021","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.thromres.2022.01.019_bb0085","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.beha.2014.04.005","article-title":"The coagulopathy in acute promyelocytic leukaemia\u2013what have we learned in the past twenty years","volume":"27","author":"Kwaan","year":"2014","journal-title":"Best Pract. Res. Clin. Haematol."},{"issue":"3","key":"10.1016\/j.thromres.2022.01.019_bb0090","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1182\/blood.V86.3.1072.1072","article-title":"Loss of blast cell procoagulant activity and improvement of hemostatic variables in patients with acute promyelocytic leukemia administered all-trans-retinoic acid","volume":"86","author":"Falanga","year":"1995","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.thromres.2022.01.019_bb0095","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/j.ctrv.2014.01.001","article-title":"Retinoids and breast cancer: from basic studies to the clinic and back again","volume":"40","author":"Garattini","year":"2014","journal-title":"Cancer Treat. Rev."},{"issue":"10","key":"10.1016\/j.thromres.2022.01.019_bb0100","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12103027","article-title":"Retinoic acid sensitivity of triple-negative breast cancer cells characterized by constitutive activation of the notch1 pathway: the role of rarbeta","volume":"12","author":"Paroni","year":"2020","journal-title":"Cancers"},{"issue":"5","key":"10.1016\/j.thromres.2022.01.019_bb0105","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1200\/JCO.19.01461","article-title":"Venous thromboembolism prophylaxis and treatment in patients with cancer: ASCO clinical practice guideline update","volume":"38","author":"Key","year":"2020","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"issue":"7","key":"10.1016\/j.thromres.2022.01.019_bb0110","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1080\/07357907.2017.1340480","article-title":"Long term low molecular weight heparin anticoagulant therapy modulates thrombin generation and D-dimer in patients with cancer and venous thromboembolism","volume":"35","author":"D'Alessio","year":"2017","journal-title":"Cancer Investig."},{"issue":"2","key":"10.1016\/j.thromres.2022.01.019_bb0115","doi-asserted-by":"crossref","first-page":"153","DOI":"10.3109\/07357907.2010.543217","article-title":"LMWH bemiparin and ULMWH RO-14 reduce the endothelial angiogenic features elicited by leukemia, lung cancer, or breast cancer cells","volume":"29","author":"Vignoli","year":"2011","journal-title":"Cancer Investig."},{"key":"10.1016\/j.thromres.2022.01.019_bb0120","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.thromres.2017.06.037","article-title":"Heparins inhibit the endothelial pro-thrombotic features induced by tumor cells","volume":"157","author":"Vignoli","year":"2017","journal-title":"Thromb. Res."},{"issue":"8","key":"10.1016\/j.thromres.2022.01.019_bb0125","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.3324\/haematol.2011.055343","article-title":"Characterization of the thrombin generation potential of leukemic and solid tumor cells by calibrated automated thrombography","volume":"97","author":"Marchetti","year":"2012","journal-title":"Haematologica"},{"issue":"6","key":"10.1016\/j.thromres.2022.01.019_bb0130","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1016\/j.thromres.2015.08.009","article-title":"Cancer cells BXPC3 and MCF7 differentially reverse the inhibition of thrombin generation by apixaban, fondaparinux and enoxaparin","volume":"136","author":"Rousseau","year":"2015","journal-title":"Thromb. Res."},{"issue":"2","key":"10.1016\/j.thromres.2022.01.019_bb0135","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/BF02981930","article-title":"The role of the hemostatic system in tumor growth, metastasis, and angiogenesis: tissue factor is a bifunctional molecule capable of inducing both fibrin deposition and angiogenesis in cancer","volume":"73","author":"Rickles","year":"2001","journal-title":"Int. J. Hematol."},{"issue":"1","key":"10.1016\/j.thromres.2022.01.019_bb0140","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.bbrc.2018.05.136","article-title":"Tissue factor mediates microvesicles shedding from MDA-MB-231 breast cancer cells","volume":"502","author":"Rondon","year":"2018","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"8","key":"10.1016\/j.thromres.2022.01.019_bb0145","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1055\/s-0030-1267043","article-title":"Microparticles in cancer","volume":"36","author":"Rak","year":"2010","journal-title":"Semin. Thromb. Hemost."},{"issue":"Suppl 1","key":"10.1016\/j.thromres.2022.01.019_bb0150","doi-asserted-by":"crossref","first-page":"S132","DOI":"10.1016\/S0049-3848(12)70033-6","article-title":"Microparticles in tumor progression","volume":"129","author":"Falanga","year":"2012","journal-title":"Thromb. Res."},{"issue":"15","key":"10.1016\/j.thromres.2022.01.019_bb0155","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21155195","article-title":"Platelets extracellular vesicles as regulators of cancer progression-an updated perspective","volume":"21","author":"Zmigrodzka","year":"2020","journal-title":"Int. J. Mol. Sci."},{"issue":"38","key":"10.1016\/j.thromres.2022.01.019_bb0160","doi-asserted-by":"crossref","first-page":"63265","DOI":"10.18632\/oncotarget.18792","article-title":"Chemotherapy administration to breast cancer patients affects extracellular vesicles thrombogenicity and function","volume":"8","author":"Aharon","year":"2017","journal-title":"Oncotarget"},{"issue":"13","key":"10.1016\/j.thromres.2022.01.019_bb0165","doi-asserted-by":"crossref","first-page":"6445","DOI":"10.7150\/thno.53637","article-title":"Phosphatidylserine-exposing tumor-derived microparticles exacerbate coagulation and cancer cell transendothelial migration in triple-negative breast cancer","volume":"11","author":"Zhang","year":"2021","journal-title":"Theranostics"},{"issue":"1","key":"10.1016\/j.thromres.2022.01.019_bb0170","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1002\/ajh.10073","article-title":"Effect of all-trans-retinoic acid on the hypercoagulable state of patients with breast cancer","volume":"70","author":"Falanga","year":"2002","journal-title":"Am. J. Hematol."},{"issue":"6","key":"10.1016\/j.thromres.2022.01.019_bb0175","first-page":"3259","article-title":"Tissue factor expression does not predict mortality in breast cancer patients","volume":"37","author":"Stampfli","year":"2017","journal-title":"Anticancer Res."},{"issue":"2","key":"10.1016\/j.thromres.2022.01.019_bb0180","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1038\/nm0296-209","article-title":"In situ detection of tissue factor in vascular endothelial cells: correlation with the malignant phenotype of human breast disease","volume":"2","author":"Contrino","year":"1996","journal-title":"Nat. Med."},{"key":"10.1016\/j.thromres.2022.01.019_bb0185","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1186\/1471-2407-10-235","article-title":"Targeting tissue factor on tumour cells and angiogenic vascular endothelial cells by factor VII-targeted verteporfin photodynamic therapy for breast cancer in vitro and in vivo in mice","volume":"10","author":"Hu","year":"2010","journal-title":"BMC Cancer"},{"issue":"6","key":"10.1016\/j.thromres.2022.01.019_bb0190","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1158\/2326-6066.CIR-17-0343","article-title":"Targeting tissue factor for immunotherapy of triple-negative breast cancer using a second-generation ICON","volume":"6","author":"Hu","year":"2018","journal-title":"Cancer Immunol. Res."},{"issue":"5","key":"10.1016\/j.thromres.2022.01.019_bb0195","doi-asserted-by":"crossref","first-page":"1768","DOI":"10.1002\/cam4.2748","article-title":"Breast cancer stromal clotting activation (Tissue factor and thrombin): a pre-invasive phenomena that is prognostic in invasion","volume":"9","author":"Shaker","year":"2020","journal-title":"Cancer Med."},{"issue":"4","key":"10.1016\/j.thromres.2022.01.019_bb0200","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2021.101033","article-title":"The role of von willebrand factor in breast cancer metastasis","volume":"14","author":"Goh","year":"2021","journal-title":"Transl. Oncol."},{"issue":"10","key":"10.1016\/j.thromres.2022.01.019_bb0205","doi-asserted-by":"crossref","first-page":"2444","DOI":"10.1111\/jth.14976","article-title":"Von willebrand factor and cancer; metastasis and coagulopathies","volume":"18","author":"Patmore","year":"2020","journal-title":"J. Thromb. Haemos"},{"issue":"9","key":"10.1016\/j.thromres.2022.01.019_bb0210","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1002\/ijc.29847","article-title":"Platelets in cancer metastasis: to help the \"villain\" to do evil","volume":"138","author":"Li","year":"2016","journal-title":"Int. J. Cancer"},{"issue":"3","key":"10.1016\/j.thromres.2022.01.019_bb0215","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/S0022-2143(97)90182-7","article-title":"Human breast carcinoma cells synthesize a protein immunorelated to platelet glycoprotein-ib alpha with different functional properties","volume":"129","author":"Oleksowicz","year":"1997","journal-title":"J. Lab. Clin. Med."},{"issue":"4","key":"10.1016\/j.thromres.2022.01.019_bb0220","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1073\/pnas.98.4.1853","article-title":"Integrin activation controls metastasis in human breast cancer","volume":"98","author":"Felding-Habermann","year":"2001","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"9","key":"10.1016\/j.thromres.2022.01.019_bb0225","first-page":"1125","article-title":"von Willebrand factor antigen levels in plasma of patients with malignant breast disease","volume":"34","author":"Rohsig","year":"2001"},{"issue":"2A","key":"10.1016\/j.thromres.2022.01.019_bb0230","first-page":"1107","article-title":"Circulating microparticles in breast cancer patients: a comparative analysis with established biomarkers","volume":"28","author":"Toth","year":"2008","journal-title":"Anticancer Res."},{"issue":"Suppl 1","key":"10.1016\/j.thromres.2022.01.019_bb0235","doi-asserted-by":"crossref","first-page":"S55","DOI":"10.1016\/S0049-3848(16)30099-8","article-title":"Hypercoagulation screening as an innovative tool for risk assessment, early diagnosis and prognosis in cancer: the HYPERCAN study","volume":"140","author":"A. Falanga","year":"2016","journal-title":"Thromb. Res."},{"issue":"4","key":"10.1016\/j.thromres.2022.01.019_bb0240","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1055\/s-0040-1718531","article-title":"Tissue plasminogen activator levels and risk of breast cancer in a case-cohort study on Italian women: results from the Moli-sani study","volume":"121","author":"Costanzo","year":"2021","journal-title":"Thromb. Haemost."},{"issue":"Suppl 1","key":"10.1016\/j.thromres.2022.01.019_bb0245","doi-asserted-by":"crossref","first-page":"S54","DOI":"10.1016\/j.thromres.2018.01.017","article-title":"Hemostatic biomarkers in cancer progression","volume":"164","author":"Falanga","year":"2018","journal-title":"Thromb. Res."},{"issue":"6","key":"10.1016\/j.thromres.2022.01.019_bb0250","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.3324\/haematol.2019.228981","article-title":"Thrombotic biomarkers for risk prediction of malignant disease recurrence in patients with early stage breast cancer","volume":"105","author":"Giaccherini","year":"2020","journal-title":"Haematologica"},{"issue":"3","key":"10.1016\/j.thromres.2022.01.019_bb0255","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.thromres.2011.10.017","article-title":"Thrombin generation in clinical conditions","volume":"129","author":"Ten Cate","year":"2012","journal-title":"Thromb. Res."},{"issue":"1","key":"10.1016\/j.thromres.2022.01.019_bb0260","doi-asserted-by":"crossref","first-page":"e56","DOI":"10.1055\/s-0040-1722609","article-title":"Validation of the role of thrombin generation potential by a fully automated system in the identification of breast cancer patients at high risk of disease recurrence","volume":"5","author":"Gomez-Rosas","year":"2021","journal-title":"TH Open"}],"container-title":["Thrombosis Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049384822000196?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049384822000196?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T14:26:05Z","timestamp":1777472765000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0049384822000196"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5]]},"references-count":52,"alternative-id":["S0049384822000196"],"URL":"https:\/\/doi.org\/10.1016\/j.thromres.2022.01.019","relation":{},"ISSN":["0049-3848"],"issn-type":[{"value":"0049-3848","type":"print"}],"subject":[],"published":{"date-parts":[[2022,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Hemostatic system activation in breast cancer: Searching for new biomarkers for cancer risk prediction and outcomes","name":"articletitle","label":"Article Title"},{"value":"Thrombosis Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.thromres.2022.01.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}